The treatment of metastatic cancer has developed significantly over the past decade.
Median survival time after chemotherapy was reported to be 12 months for gastric cancer. Several clinical trials reported for more than 2 years by introduction of molecular targeting agents, such as bevacizumab, cetuximab and panitumumab for colorectal cancer. In this article we review various treatment options, including cytotoxic and molecular targeted agents, currently available for patients with gastric or colorectal cancer in Japan.
